A Study of Aneustat (OMN54) in Patients With Advanced Cancer and Lymphomas
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This is a phase I, open-label, multiple dose, dose escalation study to assess the safety,
tolerability and pharmacokinetics of Aneustat™ (OMN54), a novel therapy, administered orally
in patients with advanced cancer and lymphomas.